169 Results for "

TRKA

" in MedChemExpress (MCE) Product Catalog:
Products (169)

169 Results for "TRKA" in MCE Product Catalog:

  • Categories Recommended:
    More
2
2 Cited Publications
Art. -Nr.: HY-P99221
CAS. Nr.: 880266-57-9
Synonyms: RN-624; PF 4383119

Target:  

Trk Receptor

Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia .
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-17603
CAS. Nr.: 1357920-84-3
Synonyms: TSR-011
Forschungsgebiete:  

Cancer

Belizatinib (TSR-011) is an orally active, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-P76116
Reinheit:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NTRK1; Tyrosine Kinase Receptor A; Neurotrophic Receptor Tyrosine Kinase 1; P140-TRKA; TRKA; Gp140trk; TRK; Trk-A; MTC; Neurotrophic Tyrosine Kinase Receptor Type 1; High Affinity Nerve Growth Factor Receptor; Tyrosine-Protein Kinase Receptor; Neurotrophi
Species:  
Mouse
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-P7308
Reinheit:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: NTRK1; Tyrosine Kinase Receptor A; Neurotrophic Receptor Tyrosine Kinase 1; P140-TRKA; TRKA; Gp140trk; TRK; Trk-A; MTC; Neurotrophic Tyrosine Kinase Receptor Type 1; High Affinity Nerve Growth Factor Receptor; Tyrosine-Protein Kinase Receptor; Neurotrophic Tyrosine Kinase, Receptor, Type 1; Tyrosine Kinase Receptor; TRK1-Transforming Tyrosine Kinase Protein; Oncogene TRK; Tropomyosin Receptor Kinase A; TRK1; Tropomyosin-Related Kinase A
Species:  
Human
Source:  
HEK293
loading...
    loading...
1
1 Cited Publications
Art. -Nr.: HY-14604
CAS. Nr.: 90494-79-4
Reinheit:  98.57%
Synonyms: SR57746A; SR57746 hydrochloride
Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
loading...
    loading...
Art. -Nr.: HY-137465
CAS. Nr.: 2412055-93-5
Target:  

PROTACs Trk Receptor

Forschungsgebiete:  

Cancer

CG428 is a potent and selective CRBN-dependent tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 TPM3-TRKA fusion protein in KM12 colorectal carcinoma cells (DC50 = 0.36 nM) and inhibits downstream PLCγ1 phosphorylation (IC50 = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). CG428 can be used for the research of colorectal carcinoma .
loading...
    loading...
Art. -Nr.: HY-109194
CAS. Nr.: 1458063-04-1
Reinheit:  98.46%
Synonyms: REC 0559
Target:  

Trk Receptor Apoptosis

Forschungsgebiete:  

Neurological Disease

Udonitrectag (REC 0559) is a nerve growth factor peptide mimetic and a TrkA receptor binder. Udonitrectag binds to the TrkA receptor, thereby mimicking anti-Apoptotic activity and corneal trophic activity. Udonitrectag promotes the healing of corneal epithelium and stroma. Udonitrectag is applicable to research related to neurotrophic keratitis .
loading...
    loading...
Art. -Nr.: HY-121833
CAS. Nr.: 286935-60-2
Reinheit:  95.76%
Target:  

Trk Receptor Akt ERK

Forschungsgebiete:  

Neurological Disease Cancer

Gambogic amide is a potent and selective agonist of TrkA and also induces its tyrosine phosphorylation and activation of downstream signaling, including Akt and MAPK. Gambogic amide specifically interacts with the cytoplasmic juxtamembrane domain of the TrkA receptor and triggers its dimerization, leading to activation. Gambogic amide has neuroprotective activity preventing glutamate-induced neuronal cell death. Gambogic amide has improved efficacy in a transient middle cerebral artery occlusion model of stroke and could be used to study neurodegenerative diseases and stroke .
loading...
    loading...
Art. -Nr.: HY-129634
CAS. Nr.: 1680179-43-4
Reinheit:  96.46%
Target:  

Trk Receptor

Forschungsgebiete:  

Neurological Disease

TrkA-IN-1 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor with an IC50 of 99 nM in a cell-based assay. TrkA-IN-1 has analgesic activity .
loading...
    loading...
Art. -Nr.: HY-145587
CAS. Nr.: 2353522-15-1
Reinheit:  99.96%
Synonyms: PBI-200; PPI-5278
Target:  

Tyrosinase Trk Receptor

Forschungsgebiete:  

Inflammation/Immunology Cancer

Paltimatrectinib (compound I-147) is a potent tyrosine kinase inhibitor with an IC50 of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases .
loading...
    loading...
Art. -Nr.: HY-112436
CAS. Nr.: 1799788-94-5
Reinheit:  99.41%
Synonyms: Trk-IN-4
Target:  

Trk Receptor

Forschungsgebiete:  

Neurological Disease

PF-6683324 (Trk-IN-4) is a potent pan-Trk inhibitor in cell-based assays with IC50s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .
loading...
    loading...
Art. -Nr.: HY-151948
CAS. Nr.: 3026111-73-6
Reinheit:  98.46%
Target:  

Trk Receptor

Forschungsgebiete:  

Neurological Disease

TrkA-IN-3 is a potent, subselective and allosteric TrkA inhibitor, with an IC50 of 22.4 nM. TrkA-IN-3 shows more than 8000-fold selectivity for TrkA over TrkB and TrkC. TrkA-IN-3 can be used for the research of pain .
loading...
    loading...
Art. -Nr.: HY-151949
CAS. Nr.: 3026111-74-7
Reinheit:  99.90%
Target:  

Trk Receptor

Forschungsgebiete:  

Neurological Disease

TrkA-IN-4, a potent, orally active and allosteric TrkA inhibitor, is a proagent of TrkA-IN-3 (IC50=22.4 nM, HY-151948). TrkA-IN-4 exhibits potent antinociceptive effects .
loading...
    loading...
Art. -Nr.: HY-157542
CAS. Nr.: 2714560-39-9
Target:  

PROTACs Trk Receptor

Forschungsgebiete:  

Cancer

CG428-NEG is the negative control of PROTAC CG428 (HY-137465). CG428-NEG binds to TRKA, TRKB and TRKC with high affinity, with Kd values of 0.88 nM, 4.8 nM and 59.8 nM, respectively. CG428-NEG inhibits the growth of cancer cells and reduces the level of TPM3-TRKA fusion protein in cancer cells. CG428-NEG can be used in the research of colorectal cancer .
loading...
    loading...
Art. -Nr.: HY-112471
CAS. Nr.: 388626-12-8
Target:  

CDK

Forschungsgebiete:  

Cancer

TrkA Inhibitor (Compound 18) is a CDK2 inhibitor with an IC50 of 0.69  μM over CDK1. TrkA Inhibitor can be used for chemotherapy-induced alopecia research .
loading...
    loading...
Art. -Nr.: HY-112437
CAS. Nr.: 1863905-38-7
Reinheit:  99.70%
Target:  

Trk Receptor

Forschungsgebiete:  

Neurological Disease

PF-06737007 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 7.7 nM, 15 nM and 3.9 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .
loading...
    loading...
Art. -Nr.: HY-171450
CAS. Nr.: 1802770-18-8
Target:  

Trk Receptor

Forschungsgebiete:  

Cancer

VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma .
loading...
    loading...
Art. -Nr.: HY-19704
CAS. Nr.: 1233363-33-1
Synonyms: CT327; SNA-120
Target:  

Trk Receptor

Forschungsgebiete:  

Inflammation/Immunology Cancer

Pegcantratinib (CT327) is a potent and selective TRKA antagonist with activity against TRKB and TRKC. Pegcantratinib can be used for research of CYLD cutaneous syndrome (CCS) and inflammatory dermatoses, such as psoriasis and concomitant pruritus .
loading...
    loading...
Art. -Nr.: HY-E70869
Target:  

Trk Receptor

Forschungsgebiete:  

Neurological Disease

TRKA (also named NTRK1) is a potential new member of the tyrosine kinase gene family. TRKA is a receptor tyrosine kinase that is phosphorylated in response to NGF. A single transmembrane domain divides TRKA into an extracellular domain, important for NGF binding, and an intracellular tyrosine kinase domain, important for signal transduction. TRKA(NTRK1) Recombinant Human Active Protein Kinase is a recombinant TRKA(NTRK1) protein that can be used to study TRKA(NTRK1)-related functions .
loading...
    loading...
Art. -Nr.: HY-141864
CAS. Nr.: 2655557-54-1
Target:  

Itk

Forschungsgebiete:  

Inflammation/Immunology

ITK/TRKA-IN-1 is a dual inhibitor of IL-2-inducible T-cell kinase (ITK) and tropomyosin receptor kinase A (TRKA) with an IC50 value of 1.0 nM and 96 % inhibition, respectively.
loading...
    loading...